ATE251625T1 - 8-phenyl-6,9-dihydro-(1,2,4)triazolo(3,4-i)puri - 5-on derivate - Google Patents

8-phenyl-6,9-dihydro-(1,2,4)triazolo(3,4-i)puri - 5-on derivate

Info

Publication number
ATE251625T1
ATE251625T1 AT00949400T AT00949400T ATE251625T1 AT E251625 T1 ATE251625 T1 AT E251625T1 AT 00949400 T AT00949400 T AT 00949400T AT 00949400 T AT00949400 T AT 00949400T AT E251625 T1 ATE251625 T1 AT E251625T1
Authority
AT
Austria
Prior art keywords
puri
triazolo
dihydro
phenyl
derivatives
Prior art date
Application number
AT00949400T
Other languages
English (en)
Inventor
Ferrer Jordi Gracia
Gras Joan Feixas
Soto Jose Manuel Prieto
Noverola Armando Vega
Juan Bernat Vidal
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Application granted granted Critical
Publication of ATE251625T1 publication Critical patent/ATE251625T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT00949400T 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-(1,2,4)triazolo(3,4-i)puri - 5-on derivate ATE251625T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009901694A ES2166270B1 (es) 1999-07-27 1999-07-27 Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
PCT/EP2000/007062 WO2001007441A1 (en) 1999-07-27 2000-07-24 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES

Publications (1)

Publication Number Publication Date
ATE251625T1 true ATE251625T1 (de) 2003-10-15

Family

ID=8309393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00949400T ATE251625T1 (de) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-(1,2,4)triazolo(3,4-i)puri - 5-on derivate

Country Status (34)

Country Link
US (1) US7034016B2 (de)
EP (1) EP1198464B1 (de)
JP (1) JP2003505461A (de)
KR (1) KR20020022786A (de)
CN (1) CN1198825C (de)
AR (1) AR024969A1 (de)
AT (1) ATE251625T1 (de)
AU (1) AU777571B2 (de)
BG (1) BG106346A (de)
BR (1) BR0012764A (de)
CA (1) CA2380181A1 (de)
CO (1) CO5190717A1 (de)
CZ (1) CZ2002311A3 (de)
DE (1) DE60005838T2 (de)
DK (1) DK1198464T3 (de)
EE (1) EE200200046A (de)
ES (2) ES2166270B1 (de)
HK (1) HK1044332B (de)
HU (1) HUP0202103A3 (de)
IL (1) IL147770A0 (de)
MY (1) MY129590A (de)
NO (1) NO20020391L (de)
NZ (1) NZ516780A (de)
PE (1) PE20010401A1 (de)
PL (1) PL353827A1 (de)
PT (1) PT1198464E (de)
RU (1) RU2258705C2 (de)
SK (1) SK1352002A3 (de)
TR (1) TR200200785T2 (de)
TW (1) TW568912B (de)
UA (1) UA73513C2 (de)
UY (1) UY26258A1 (de)
WO (1) WO2001007441A1 (de)
ZA (1) ZA200200561B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127506C (zh) 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE0300917D0 (sv) 2003-03-31 2003-03-31 St Jude Medical Multi-chamber pacing system
EP1644021B1 (de) 2003-06-13 2012-08-22 Ironwood Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1745018A1 (de) * 2004-04-29 2007-01-24 Merck & Co., Inc. Inhibitoren des azetidinglycintransporters
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
MX2007006069A (es) * 2004-11-18 2007-07-11 Schering Corp Metodos para utilizar inhibidores de la fosfodiesterasa tipo v y para el tratamiento de insuficiencia cardiaca congestiva.
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (de) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituiertes dimeres chinazolinderivat, dessen herstellung und dessen verwendung in pharmazeutischen zusammensetzungen zur behandlung von diabetes typ i und ii
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
SG11201408395WA (en) 2012-06-18 2015-01-29 Dart Neuroscience Cayman Ltd Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
EP3468562A1 (de) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Kombinationen aus linagliptin und metformin
AU2019205661B2 (en) * 2018-01-04 2022-06-30 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
KR20210052478A (ko) * 2018-08-30 2021-05-10 테라 스톤 가부시키가이샤 크산틴옥시다아제를 저해하기 위한 하이드라지노퓨린 화합물 및 트리아졸로퓨린 화합물
CN112225761B (zh) * 2020-12-16 2021-03-12 南京颐媛生物医学研究院有限公司 一种嘧啶并三氮唑及其合成方法
EP4305033A1 (de) * 2021-03-09 2024-01-17 Basf Se Tricyclische pestizide verbindungen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
DE3347290A1 (de) * 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
JP2980658B2 (ja) * 1989-09-14 1999-11-22 協和醗酵工業株式会社 ｓ―トリアゾロ〔３，４―ｉ〕プリン誘導体
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
CA2213420A1 (en) * 1995-02-21 1996-08-29 Kazuki Endo Purine compounds and xanthine oxidase inhibitors
NZ338075A (en) * 1997-04-25 2000-10-27 Pfizer Ltd Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PED5) for the treatment of sexual dysfunction
AU4501199A (en) * 1998-06-03 1999-12-20 Almirall Prodesfarma S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
JP2004505980A (ja) * 2000-08-09 2004-02-26 アルミラル　プロデスファルマ　ソシエダ　アノニマ ピロロトリアゾロピリミジノン誘導体

Also Published As

Publication number Publication date
ES2166270A1 (es) 2002-04-01
PE20010401A1 (es) 2001-04-16
JP2003505461A (ja) 2003-02-12
CA2380181A1 (en) 2001-02-01
CN1374962A (zh) 2002-10-16
CO5190717A1 (es) 2002-08-29
BG106346A (en) 2002-09-30
DE60005838T2 (de) 2004-08-19
DE60005838D1 (de) 2003-11-13
NO20020391D0 (no) 2002-01-25
DK1198464T3 (da) 2004-02-16
HK1044332B (zh) 2004-10-15
EP1198464B1 (de) 2003-10-08
EE200200046A (et) 2003-04-15
WO2001007441A1 (en) 2001-02-01
EP1198464A1 (de) 2002-04-24
TW568912B (en) 2004-01-01
ES2166270B1 (es) 2003-04-01
UY26258A1 (es) 2000-12-29
KR20020022786A (ko) 2002-03-27
AU6277200A (en) 2001-02-13
HUP0202103A3 (en) 2004-12-28
RU2258705C2 (ru) 2005-08-20
CN1198825C (zh) 2005-04-27
ES2208378T3 (es) 2004-06-16
NO20020391L (no) 2002-03-25
US20030060627A1 (en) 2003-03-27
ZA200200561B (en) 2003-06-25
HK1044332A1 (en) 2002-10-18
TR200200785T2 (tr) 2002-09-23
PL353827A1 (en) 2003-12-01
SK1352002A3 (en) 2003-04-01
HUP0202103A2 (en) 2002-10-28
CZ2002311A3 (cs) 2003-01-15
IL147770A0 (en) 2002-08-14
AU777571B2 (en) 2004-10-21
PT1198464E (pt) 2004-02-27
MY129590A (en) 2007-04-30
UA73513C2 (en) 2005-08-15
AR024969A1 (es) 2002-10-30
BR0012764A (pt) 2002-07-02
US7034016B2 (en) 2006-04-25
NZ516780A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
ATE251625T1 (de) 8-phenyl-6,9-dihydro-(1,2,4)triazolo(3,4-i)puri - 5-on derivate
ATE261933T1 (de) Admantan derivate
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
NO20000885D0 (no) 4-Fenyl-pyridin-derivater
NO20021077L (no) Amino-triazolopyridin-derivater
ATE263748T1 (de) Admantan-derivate
ATE293104T1 (de) Thiazolylamid-derivate
EE200100613A (et) 13-metüülerütromütsiini derivaadid
DE60013127D1 (de) 5-phenyl-pyrimidine derivate
NO20021803L (no) Isoksazolkarboksamid-derivater
ATE257148T1 (de) Propargyletherderivate
ATE273272T1 (de) Mevinolinderivate
ATE374747T1 (de) Monofluoralkylderivate
DE60025918D1 (de) 4-phenyl-pyrimidine derivate
DE60006703D1 (de) 4-hydroxybiphenylhydrazid-derivate
ATE293592T1 (de) Resorcinderivate
NO20020212L (no) 3-amino-2-benzyl-1-fenyl-propanderivater
DK1189886T3 (da) Ethansulfonyl-piperidinderivater
DK1178984T3 (da) 1-trifluormethyl-4-hydroxy-7-piperidinylaminomethylchroman-derivater
DE59909774D1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate
SI1198464T1 (en) 8-PHENYL-6,9-DIHYDRO-(1,2,4)TRIAZOLO(3,4-i)PURIN-5-ONE DERIVATIVES

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1198464

Country of ref document: EP

REN Ceased due to non-payment of the annual fee